ProCE Banner Activity

My Approach to Talking With Patients With Advanced NSCLC: Frontline Immunotherapy Options

Clinical Thought
How do you involve your patients in treatment decisions? Read my take on helping patients understand and consider which immunotherapy approach best matches their goals.

Released: November 12, 2020

Expiration: November 11, 2021

No longer available for credit.

Share

Faculty

Sandip P. Patel

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Partners

GRACE

ProCE Banner

Faculty Disclosure

Primary Author

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

Sandip P. Patel, MD, has disclosed that he has served on advisory boards/as a consultant for AstraZeneca, Bristol-Myers Squibb, and Merck and has received funds for research support from AstraZeneca, Bristol-Myers Squibb, Nektar, Guardant, Illumina, Lilly, and Tempus.